248 related articles for article (PubMed ID: 34307658)
41. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
Lampignano R; Neumann MHD; Weber S; Kloten V; Herdean A; Voss T; Groelz D; Babayan A; Tibbesma M; Schlumpberger M; Chemi F; Rothwell DG; Wikman H; Galizzi JP; Riise Bergheim I; Russnes H; Mussolin B; Bonin S; Voigt C; Musa H; Pinzani P; Lianidou E; Brady G; Speicher MR; Pantel K; Betsou F; Schuuring E; Kubista M; Ammerlaan W; Sprenger-Haussels M; Schlange T; Heitzer E
Clin Chem; 2020 Jan; 66(1):149-160. PubMed ID: 31628139
[TBL] [Abstract][Full Text] [Related]
42. Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.
Sorber L; Zwaenepoel K; Jacobs J; De Winne K; Van Casteren K; Augustus E; Lardon F; Prenen H; Peeters M; Van Meerbeeck J; Roeyen G; Rolfo C; Pauwels P
Mol Diagn Ther; 2020 Feb; 24(1):113-124. PubMed ID: 31838654
[TBL] [Abstract][Full Text] [Related]
43. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
45. Extraction of Cell-Free DNA: Evaluation of Efficiency, Quantity, and Quality.
Terp SK; Pedersen IS; Stoico MP
J Mol Diagn; 2024 Apr; 26(4):310-319. PubMed ID: 38336350
[TBL] [Abstract][Full Text] [Related]
46. The Combining Effects of Cell-Free Circulating Tumor DNA of Breast Tumor to the Noninvasive Prenatal Testing Results: A Simulating Investigation.
Cai YH; Yao GY; Chen LJ; Gan HY; Ye CS; Yang XX
DNA Cell Biol; 2018 Jul; 37(7):626-633. PubMed ID: 29957029
[TBL] [Abstract][Full Text] [Related]
47. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
[TBL] [Abstract][Full Text] [Related]
48. Optimized (Pre) Analytical Conditions and Workflow for Droplet Digital PCR Analysis of Cell-Free DNA from Patients with Suspected Lung Carcinoma.
de Kock R; Deiman B; Kraaijvanger R; Scharnhorst V
J Mol Diagn; 2019 Sep; 21(5):895-902. PubMed ID: 31229652
[TBL] [Abstract][Full Text] [Related]
49. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
50. A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA.
Janku F; Huang HJ; Pereira DY; Kobayashi M; Chiu CH; Call SG; Woodbury KT; Chao F; Marshak DR; Chiu RYT
Sci Rep; 2021 Oct; 11(1):19653. PubMed ID: 34608196
[TBL] [Abstract][Full Text] [Related]
51. Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.
Sorber L; Zwaenepoel K; Jacobs J; De Winne K; Goethals S; Reclusa P; Van Casteren K; Augustus E; Lardon F; Roeyen G; Peeters M; Van Meerbeeck J; Rolfo C; Pauwels P
Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30935089
[TBL] [Abstract][Full Text] [Related]
52. International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.
Keppens C; Dequeker EMC; Patton SJ; Normanno N; Fenizia F; Butler R; Cheetham M; Fairley JA; Williams H; Hall JA; Schuuring E; Deans ZC;
BMC Cancer; 2018 Aug; 18(1):804. PubMed ID: 30092778
[TBL] [Abstract][Full Text] [Related]
53. Cell-Free Microbial DNA Analysis: Effects of Blood Plasma and Serum Quantity, Biobanking Protocols, and Isolation Kits.
Nikitina D; Lukosevicius R; Tilinde D; Muskieta T; Hov JR; Melum E; Klovins J; Org E; Kiudelis G; Kupcinskas J; Skieceviciene J
Biopreserv Biobank; 2024 Feb; ():. PubMed ID: 38416864
[TBL] [Abstract][Full Text] [Related]
54. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.
van Dessel LF; Vitale SR; Helmijr JCA; Wilting SM; van der Vlugt-Daane M; Oomen-de Hoop E; Sleijfer S; Martens JWM; Jansen MPHM; Lolkema MP
Mol Oncol; 2019 Feb; 13(2):392-402. PubMed ID: 30516338
[TBL] [Abstract][Full Text] [Related]
55. Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation.
Mojtabanezhad Shariatpanahi A; Rokni P; Shahabi E; Varshoee Tabrizi F; Kerachian MA
BMC Res Notes; 2018 Oct; 11(1):757. PubMed ID: 30352614
[TBL] [Abstract][Full Text] [Related]
56. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing.
Wong D; Moturi S; Angkachatchai V; Mueller R; DeSantis G; van den Boom D; Ehrich M
Clin Biochem; 2013 Aug; 46(12):1099-1104. PubMed ID: 23643886
[TBL] [Abstract][Full Text] [Related]
57. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
58. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
59. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
60. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
